Raymond James Initiates AnaptysBio With ~42% Upside, Despite Trial Setback
Raymond James initiated coverage on AnaptysBio Inc (NASDAQ:ANAB) with an Outperform rating and a $35 price target. The analyst has a positive…
AnaptysBio Faces Another Setback For Imsidolimab, Stalls Work In Skin Scarring Indication
AnaptysBio Inc (NASDAQ: ANAB) announced topline data from its HARP Phase 2 trial of imsidolimab for moderate-to-severe hidradenitis suppurativa (HS).
Raymond James Initiates Coverage On AnaptysBio with Outperform Rating, Announces Price Target of $35
Raymond James analyst Steven Seedhouse initiates coverage on AnaptysBio (NASDAQ:ANAB) with a Outperform rating and announces Price Target of $35.
